VAXCYTE INC's ticker is PCVX and the CUSIP is 92243G108. A total of 201 filers reported holding VAXCYTE INC in Q3 2023. The put-call ratio across all filers is 0.83 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $21,876,232 | -1.7% | 429,114 | -3.8% | 0.00% | 0.0% |
| Q2 2023 | $22,265,499 | +19.2% | 445,845 | -10.5% | 0.00% | 0.0% |
| Q1 2023 | $18,678,195 | -2.5% | 498,351 | +24.8% | 0.00% | 0.0% |
| Q4 2022 | $19,149,503 | +63.5% | 399,364 | -18.1% | 0.00% | +33.3% |
| Q3 2022 | $11,709,000 | +52.3% | 487,883 | +38.1% | 0.00% | +50.0% |
| Q2 2022 | $7,690,000 | -7.0% | 353,381 | +3.2% | 0.00% | 0.0% |
| Q1 2022 | $8,273,000 | +75.2% | 342,551 | +72.6% | 0.00% | +100.0% |
| Q4 2021 | $4,722,000 | -24.4% | 198,477 | -19.4% | 0.00% | 0.0% |
| Q3 2021 | $6,248,000 | +49.6% | 246,294 | +32.7% | 0.00% | 0.0% |
| Q2 2021 | $4,177,000 | +16.8% | 185,585 | +2.5% | 0.00% | 0.0% |
| Q1 2021 | $3,577,000 | -54.5% | 181,100 | -38.8% | 0.00% | -50.0% |
| Q4 2020 | $7,863,000 | +184.6% | 295,908 | +238.5% | 0.00% | +100.0% |
| Q2 2020 | $2,763,000 | – | 87,424 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 1,049,893 | $53,523,545 | 17.09% |
| Pivotal bioVenture Partners Investment Advisor LLC | 793,036 | $40,429,128 | 16.12% |
| Kynam Capital Management, LP | 1,302,407 | $66,396,709 | 10.86% |
| RA Capital Management | 7,891,254 | $402,296,129 | 7.92% |
| COMMODORE CAPITAL LP | 1,100,000 | $56,078,000 | 6.56% |
| GREAT POINT PARTNERS LLC | 531,211 | $27,081,137 | 4.93% |
| ACUTA CAPITAL PARTNERS, LLC | 121,022 | $6,169,702 | 4.14% |
| Frazier Life Sciences Management, L.P. | 1,164,405 | $59,361,367 | 3.94% |
| Novo Holdings A/S | 845,000 | $43,078,100 | 3.18% |
| BRAIDWELL LP | 1,619,553 | $82,564,812 | 2.61% |